AVTR vs UTHR
Avantor vs United Therapeutics — AI-powered side-by-side comparison
VS
UTHR
United Therapeutics
70
Buy
| Metric | AVTR | UTHR |
|---|
| AI Score |
55
|
70
|
| Price |
$14.46
|
$515.99
|
| P/E Ratio |
-17.19×
|
17.15×
|
| ROE |
-9.5%
|
18.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
31.8%
|
86.1%
|
| Debt / Equity |
0.66×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
68.8
|
51.0
|
| Beta |
0.888
|
0.564
|
| Expected Upside |
+0.1%
|
+0.1%
|
AI Committee View
Current Innellis committee reasoning for AVTR versus UTHR.
UTHR leads by 15 points.
UTHR scores 70/100 (Buy) versus AVTR at 55/100 (Watch).
AVTR Committee View
80% agreement
5 analysts
The committee sees neither a compelling opportunity nor a clear risk at this stage. Conditions remain neutral — patience is warranted.
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- ROE of only -10.3% -- cheap may mean cheap for a reason — Value
- Revenue declining -1.6% YoY -- this is not a growth story right now — Growth
- MACD histogram negative -- bearish momentum — Technical
UTHR Committee View
100% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
- Lower Highs / Lower Lows structure confirms bearish price action.
- Risk/reward is unfavorable: 11.7% downside vs 0.1% upside.